BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241202T100000
DTEND;TZID=Europe/Vienna:20241202T110000
DTSTAMP:20260422T022302
CREATED:20240702T080051Z
LAST-MODIFIED:20241119T122958Z
UID:1737-1733133600-1733137200@esmit.eanm.org
SUMMARY:Japanese vs. European View on Amyloid Imaging and Therapy (in collaboration with JSNM)
DESCRIPTION:The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However\, due to differences in clinical processes and insurance systems in each country\, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe\, CSF diagnosis is often performed first and amyloid PET is performed in selected patients. In Japan\, only either CSF diagnosis or amyloid PET is covered by public insurance\, so there is a trend toward performing the more expensive PET first. The use of amyloid PET in the setting of anti-AB therapy monitoring\, and its exact positioning in the biomarkers  flow-chart is not yet clearly defined. This webinar will present recent findings on the usefulness of amyloid PET and the differences in actual use between Europe and Japan. \n\n\n\nLearning Objectives: tba \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDonatienne Van WeehaegheModerator \n\n\n\n\n\n\n\n\n\n\n\nProf. Dr. med. Dr. biol. hum. Matthias Brendel\, MHBASpeakerDepartment leadBoard certified Nuclear Medicine physician Research lead for neurodegenerative disorders LMU Klinikum   Department of Nuclear MedicineUniversity Hospital of Munich \n\n\n\n\n\nDr. Kenji IshiiSpeakerDirectorDiagnostic Neuroimaging ResearchTokyo Metropolitan Institute for Geriatrics and GerontologyTokyo\, Japan \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/japanese-vs-european-view-on-amyloid-imaging-and-therapy-in-collaboration-with-jsnm/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241206T133000
DTEND;TZID=Europe/Vienna:20241206T143000
DTSTAMP:20260422T022302
CREATED:20240213T193126Z
LAST-MODIFIED:20241203T102334Z
UID:1300-1733491800-1733495400@esmit.eanm.org
SUMMARY:Treatment of Metastatic Bone Pain Using Bone-Seeking Agents
DESCRIPTION:With the arrival of new therapeutic tracers\, nuclear medicine has a new arsenal to treat metastatic bone pain. This presentation aims to give the keys to define the place of nuclear medicine among other treatment modalities (external beam therapy\, medical treatment\, chemotherapy). \n\n\n\nLearning Objectives: Refresh knowledge on the pathophysiology of pain and present the opportunities and limitations of alpha and beta therapy in metastatic bone pain treatment \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nJules Zhang-YinModeratorArlon\, Belgium \n\n\n\n\n\n\n\n\n\n\n\nKnut LiepeSpeakerFrankfurt (Oder)\, Germany \n\n\n\n\n\nTatiana LouroSpeakerLisbon\, Portugal \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/treatment-of-metastatic-bone-pain-using-bone-seeking-agents-msk/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241212T090000
DTEND;TZID=Europe/Vienna:20241213T120000
DTSTAMP:20260422T022302
CREATED:20240213T182114Z
LAST-MODIFIED:20250116T094547Z
UID:1247-1733994000-1734091200@esmit.eanm.org
SUMMARY:Algorithms for Dementia Imaging
DESCRIPTION:UEMS EACCME has granted the accreditation of 7 CME credits for this event. \n\n\n\nThe course will offer a comprehensive overview of basic\, theoretical and practical evidence-based concepts needed for a deep and thoughtful understanding of the use of [¹⁸F]FDG (FDG) Brain PET\, amyloid (Amy) PET and DaT SPECT in Neurological Disorders. A brief introduction will be given on the position that each imaging technique holds in the recent European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Then\, short theoretical sessions on visual reading and semiquantification of FDG PET\, Amy PET and DaT SPECT will be associated with longer hands-on sessions\, for a practice-oriented learning specifically addressed to dementing disorders and neurodegenerative parkinsonian syndromes. Different approaches for semiquantification and subsequent scan reporting will be proposed and discussed. Clinical cases will be the starting point to better define the usefulness\, utility and accurate reading of PET and SPECT in Alzheimer’s disease\, other neurodegenerative dementias and Parkinsonian Syndrome.n coming soon \n\n\n\n\n\n\n\nSave yourself a seatRegistration closed. For last minute registration\, please email us at esmit@eanm.org Register now!\n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\n\nTo familiarise with the neuroimaging tools available to objectively assess brain glucose metabolism\, amyloid deposition and dopaminergic system integrity\, and their position in recent European recommendations \n\n\n\nTo learn strengths and weaknesses of different approaches for semiquantification \n\n\n\nTo appropriately choose a semi-quantitative support for image interpretation in various conditions\n\n\n\nThe course will provide important information on the most recent developments for an improved clinical practice\, of utmost importance for nuclear medicine physicians.\n\n\n\n\n\n\n\nTarget Audience\n\n\n\n\n\nGeneral nuclear medicine specialists\, radiologists who want to update their knowledge on reading\, semiquantification and reporting of FDG PET\, Amy PET and DaT SPECT in terms of clinical indications\, reading skills and pitfalls. The constantly evolving role of Brain PET in neurodegenerative disorders makes the track of interest also for neurologists who want to improve their knowledge of cutting-edge Neuroimaging tools.\n\n\n\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nValentina BertiSpeakerFlorence\, Italy \n\n\n\n\n\nIgor YakushevSpeakerMunich\, Germany \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks on each Course Day\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation. \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/algorhythms-for-dementia-imaging/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Clinical Nuclear Medicine,Onsite Course
END:VEVENT
END:VCALENDAR